Reconsidering combined antiplatelet and anticoagulant therapy in atrial fibrillation.
Rodney H
RH
Falk
D000074:Acenocoumarol / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D008946:Mitral Valve Stenosis / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012459:Salicylates / Q000009:adverse effects / Q000627:therapeutic use*; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D012459:Salicylates; C016167:triflusal; D014859:Warfarin; D000074:Acenocoumarol; D001241:Aspirin